Clinical Trial Update: BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT) [Phase 1]

View source ↗

Summary

Phase 1 trial update for BN-Brachyury, Entinostat, Adotrastuzumab Emtansine, and M7824 in advanced breast cancer; trial status terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hormone Receptor-negative Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Adotrastuzumab emtansine (ado-trastuzumab emtansine)
• BN-Brachyury
• Entinostat (entinostat)
• M7824 (bintrafusp alfa)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Breast Cancer, Triple Negative Breast Cancer | Phase 1 | Status: TERMINATED | Results posted: 2022-01-11